Latest / Bloomberg Intelligence / OPKO's Bishop on FDA Approval Of Its Kidney Disease Drug(Audio)

Transcript

OPKO's Bishop on FDA Approval Of Its Kidney Disease Drug(Audio) · Bloomberg Intelligence

• 0:03
  Speaker 1: Global business news twenty four hours a day. If Bloomberg
• 0:06
  Speaker 1: dot Com, the radio plus Mobile act and on your radio.
• 0:10
  Speaker 1: This is a Bloomberg Business Flash from Bloomberg World Headquarters.
• 0:14
  Speaker 1: I'm Catherine Coldery. We check the markets every fifteen minutes
• 0:17
  Speaker 1: throughout the trading day. Let's head over to the First
• 0:19
  Speaker 1: Word Breaking News ESK for today's afternoon call with Bill Maloney. Bill,
• 0:23
  Speaker 1: good afternoon, Catherine Sharp gains again for U S stots today.
• 0:27
  Speaker 1: DAW is currently hired by a hundred and eighty one points,
• 0:30
  Speaker 1: says Bees rise twenty two and NASA gains forty eight
• 0:34
  Speaker 1: Over in Europe, Vi Nique, I'm sorry. Over in Europe,
• 0:36
  Speaker 1: the UK climbed two point three percent. Bank of England's
• 0:39
  Speaker 1: Carney said the b O we will probably have to
• 0:41
  Speaker 1: ease policy over the summer. Back In the US, small
• 0:44
  Speaker 1: cap six hundred rises ten points and the U S
• 0:47
  Speaker 1: tenure yield at one point for eight percent. All ten
• 0:51
  Speaker 1: SV sectors are higher, led by gains in staples industrials
• 0:54
  Speaker 1: and the utilities Doubt Transports climb forty seven As a
• 0:58
  Speaker 1: botechs underperform game eight points, and the vix is down
• 1:02
  Speaker 1: by four percent. Down leaders included g E, Intel and IBM,
• 1:06
  Speaker 1: while Visa fell three and a half percent and dealing
• 1:10
  Speaker 1: those Hershey's board rejected a twenty three billion dollar takeover
• 1:13
  Speaker 1: bid from Mondols and finally look for Micron results out
• 1:17
  Speaker 1: after the bell live on the first Breaking News Desk
• 1:19
  Speaker 1: on Bill Maloney. Katherine, thank you, Bill, and to hear
• 1:22
  Speaker 1: live breaking news over your Bloomberg type s q U
• 1:24
  Speaker 1: A K on your terminal. West Texas Intermediac crude oil
• 1:28
  Speaker 1: is currently down a dollar thirty five of barrel two
• 1:30
  Speaker 1: point seven percent at three spout gold down three dollars
• 1:34
  Speaker 1: fifty cents aggounce at the ten year treasury is up
• 1:38
  Speaker 1: eleven thirty seconds with the yield of one point four
• 1:40
  Speaker 1: seven percent. And that's a Bloomberg business flash. You're listening
• 1:45
  Speaker 1: to Taking Stock with Kathleen and Pim Fox on bloom
• 1:48
  Speaker 1: Bird Radio. We are turning now to healthcare, a very
• 1:54
  Speaker 1: exciting development for up Co Health. We've had the founder
• 1:59
  Speaker 1: and head of up go on the show and the
• 2:00
  Speaker 1: Fast Dr Phil Frost, and today we're very delighted to
• 2:04
  Speaker 1: welcome Dr Charles Bishop. He's the CEO of upco's UPco
• 2:08
  Speaker 1: Health Renal division. He joins us from Miami today to
• 2:12
  Speaker 1: talk about the f d A approving reyal D. It
• 2:16
  Speaker 1: is a treatment, a drug that is going to help
• 2:19
  Speaker 1: millions of Americans with some very serious conditions. Dr Bishop,
• 2:23
  Speaker 1: welcome to the show. Kathleen, Thank you so very much.
• 2:26
  Speaker 1: You must feel uh, I mean, I know this approval
• 2:30
  Speaker 1: was expected, but still it's a very important milestone. First
• 2:34
  Speaker 1: talked to us about that. There there's two parts of this.
• 2:37
  Speaker 1: Let's start with calm chronic kidney disease and how Real
• 2:41
  Speaker 1: D fights that. Chronic kidney disease we call it t
• 2:45
  Speaker 1: k for sure, is a disorder the develops in about
• 2:51
  Speaker 1: of the American population. It's a major source of healthcare expenditures.
• 2:56
  Speaker 1: The drug Reality that was just approved by FDA does
• 3:00
  Speaker 1: not itself treat c k D. In other words, it
• 3:03
  Speaker 1: doesn't slow the disease. But what it's a proof for
• 3:07
  Speaker 1: is to treat a complication that arises with chronic kidney disease.
• 3:12
  Speaker 1: That complication is secondary hyperparathyroidism arising from vitamin D insufficiency.
• 3:19
  Speaker 1: And this is a very serious condition because secondary hyperparathyroidism
• 3:25
  Speaker 1: SHPT prevents the body producing enough vitamin D hormone to
• 3:30
  Speaker 1: regulate calcium and phosphorus metabolism, so their bones start softening.
• 3:36
  Speaker 1: That's correct. If you have kidney disease and it's progressing
• 3:40
  Speaker 1: and you're not paying attention to whether you're managing secondary hyperparathyroidism,
• 3:46
  Speaker 1: you are going to have complications with regard to your skeleton.
• 3:50
  Speaker 1: You find that as SHPT as we call it, progresses,
• 3:55
  Speaker 1: patients lose their bones and the calcium and phosphorus lost
• 3:59
  Speaker 1: from the bones is deposited in the lining or the
• 4:03
  Speaker 1: media of the arteries and in the heart, and the
• 4:07
  Speaker 1: consequence of this is that the arteries become calcified, hardened,
• 4:14
  Speaker 1: They put a lot of burden on the heart and
• 4:16
  Speaker 1: the cardiovascular events arise. So you find the patients with
• 4:20
  Speaker 1: chronic kidney disease don't typically have morbidity and mortality related
• 4:26
  Speaker 1: to renal insufficiency or kidney insufficiency. Rather, they have morbidity
• 4:32
  Speaker 1: and mortality arising from cardiovascular events that are caused by
• 4:37
  Speaker 1: vascular classification, and that vascular calcification, of course, is driven
• 4:42
  Speaker 1: by SHP. Now you became part of OpCo and serving
• 4:47
  Speaker 1: as the OpCo Real Division chief when OpCo acquired Cytochroma
• 4:53
  Speaker 1: back in I could long long career of many steps
• 4:57
  Speaker 1: in it, but I just want to particularly focus on
• 5:00
  Speaker 1: eighty seven to two thousand five, when you held various
• 5:04
  Speaker 1: management positions at bone Care International. So you've been looking
• 5:08
  Speaker 1: at developing and commercializing vitamin D therapies for a long time.
• 5:11
  Speaker 1: What was the hardest part was the biggest challenge in
• 5:14
  Speaker 1: developing reality, Well, always in developing new drugs, especially in
• 5:19
  Speaker 1: startup pharma, it's it's a big challenge to raise the
• 5:23
  Speaker 1: required funding in order to pay for the clinical trials.
• 5:27
  Speaker 1: At Bunker International, I was the first employee and I
• 5:30
  Speaker 1: ran that company for most of its existence until it
• 5:33
  Speaker 1: was sold to gen Time for seven hundred and twenty
• 5:36
  Speaker 1: million dollars. During the course of that history of Bunker International,
• 5:43
  Speaker 1: we were that we developed a new therapy for secondary
• 5:48
  Speaker 1: hyper carethrotism and got it approved for dialysis patients as
• 5:52
  Speaker 1: well as for pre dialysis patients. In fact, this drug,
• 5:56
  Speaker 1: called Hectoral, was the first modern vitamin need therapy to
• 6:01
  Speaker 1: treat secondary hyperparaviroidism. But the biggest challenge was raising the cash.
• 6:06
  Speaker 1: And the same thing is true inside of Chroma. After
• 6:09
  Speaker 1: I left bone Care with the acquisition by a gen Zime,
• 6:15
  Speaker 1: I started a new company that began working on Reality.
• 6:18
  Speaker 1: That company was called Prevented Therapeutics. Prevent If Therapeutics was
• 6:22
  Speaker 1: acquired by Side of Chroma became the president CEO of
• 6:25
  Speaker 1: side of Chroma. Then again the same challenge raising enough
• 6:29
  Speaker 1: cash to get the drug accrudi. So the bottom line
• 6:32
  Speaker 1: of APCO Health, what does this approval of Railty mean
• 6:35
  Speaker 1: and what what kind of revenue booster are sales of
• 6:39
  Speaker 1: the drug going to mean for you? Raality is an
• 6:41
  Speaker 1: exciting product. It's the first drug to be approved for
• 6:45
  Speaker 1: this indication. There's no other drug anywhere in the world
• 6:48
  Speaker 1: that's been approved to treat the indication of secondary hyperpare
• 6:52
  Speaker 1: virreutism arising in prediallysis patients as a consequence of itemint insufficiency.
• 7:00
  Speaker 1: We will be able to move Reality into the US
• 7:04
  Speaker 1: market as the first effective treatment for this particular disorder,
• 7:11
  Speaker 1: and I'm expecting that it could drive very major sales
• 7:14
  Speaker 1: for OpCo. Well. Dr Charles Bishop, thank you so much
• 7:17
  Speaker 1: for joining me today on taking stock. He's the CEO
• 7:21
  Speaker 1: of Optico Health Renal Division, joining me today from Miami, Florida,
• 7:26
  Speaker 1: talking about the approval of real D. As he said,
• 7:29
  Speaker 1: treating this this very difficult disease secondary hyperthyroidism. UH. The
• 7:34
  Speaker 1: only drug in US that will be able to treat
• 7:36
  Speaker 1: it so effectively. I'm caffeine Hayes. This is taking stock,
• 7:40
  Speaker 1: and this is Bloomberg Bloomer. Taking Stock is brought to
• 7:47
  Speaker 1: you by Bank of America Merrill Lynch, committed to bringing
• 7:49
  Speaker 1: higher finance to lower carbon named the most innovative investment
• 7:52
  Speaker 1: bank for climate change and sustainability by the Banker. That's
• 7:55
  Speaker 1: the power of global connections. Bank of America N A,
• 7:57
  Speaker 1: F D I C